<DOC>
	<DOCNO>NCT01269281</DOCNO>
	<brief_summary>The objective study compare relative bioavailability Sumatriptan Succinate Tablets 100 mg Imitrex Tablets 100 mg feed condition healthy adult human subject .</brief_summary>
	<brief_title>Bioequivalence Study Sumatriptan Succinate Tablets 100 mg Fed Conditions</brief_title>
	<detailed_description>Open Label , Randomized , Two way crossover , comparative evaluation relative bioavailability two formulation Sumatriptan Succinate Tablets 100 mg ( Dr. Reddy 's Laboratories Limited , India ) With Reference Formulation ImitrexÂ® 100 mg Tablet ( Glaxosmithkline , USA ) Under Fed Conditions Healthy Human Adult Subjects . 50 healthy , adult , human male subject enrol study 43 subject complete study .</detailed_description>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>1 . The subject healthy male 18 45 year . 2 . The subject screen within 21 day prior administration first dose study.. 3 . The subject BMI 18 25 kg/m2 4 . The subject able communicate effectively study personnel 5 . The subject literate able give consent 6 . If subject female volunteer Is child bear potential practicing acceptable method birth control duration study judge investigator ( ) , condom , foam , jelly , diaphragm , intrauterine device ( IUD ) , abstinence Is postmenopausal least 1 year Is surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy perform subject ) . 1 . The subject history allergic response Sumatriptan relate drug 2 . The subject history intake MAOI within two week dose 3 . The subject history drug dependence , recent history alcoholism moderate alcohol uses.. 4 . The subject significant disease clinically significant abnormal finding screen , medical history , physical examination , laboratory evaluation , ECG , Xray recordings.. 5 . The subject disease condition might compromise haemopoietic , gastrointestinal , renal , hepatic , cardiovascular , respiratory , central nervous system , diabetes , psychosis glaucoma body system . 6 . The subject history presence asthma ( include aspirin induce asthma ) nasal polyp.. 7 . The subject smoker smoke 10 cigarettes/day refrain smoking study period.. 8 . The subject history difficulty donate blood difficulty accessibility veins.. 9 . The subject donate 01 unit ( 350 ml / 450 ml ) blood within 90 day prior receive first dose study medication ( blood loss equal 200mL , subject enrol trial 60 day donation ) . 10 . The subject positive hepatitis screen include hepatitis B surface antigen , anti HCV , anti HEV . 11 . The subject positive test result HIV antibody / syphilis ( RPR/VDRL ) . 12 . The subject receive investigational product , participated drug research study within period 90 day prior first dose study medication administration ( elimination halflife study drug take consideration inclusion subject trial blood loss equal 200 mL ) . 13 . An unusual diet , whatever reason ( e .g . low sodium ) four week prior receive study medication throughout subject 's participation study . 14 . Female volunteer demonstrate positive pregnancy screen . 15 . Female volunteer currently breast feeding .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>two way crossover</keyword>
</DOC>